A new synthesis of cytoxazone and its diastereomers provides key initial SAR information

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 7, 2003, Pages 1237-1239

  Carter, Percy H ^a   LaPorte, Jacob R ^a   Scherle, Peggy A ^a   Decicco, Carl P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; CYTOXAZONE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DIASTEREOISOMER; DRUG ACTIVITY; ENANTIOSELECTIVITY; IMMUNOMODULATION; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TH2 CELL;

STREPTOMYCES;

EID: 0037424709     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00131-8     Document Type: Article

References (23)

1. Kakeya H., Morishita M., Kobinata K., Osono M., Ishizuka M., Osada H. J. Antibiotics. 51:1998;1126.
2. Kakeya H., Morishita M., Koshino H., Morita T., Kobayashi K., Osada H. J. Org. Chem. 64:1999;1052.
3. Sakamoto Y., Shiraishi A., Seonhee J., Nakata T. Tetrahedron Lett. 40:1999;4203.
4. (a) For reviews of the subject, see: Stirling R.G., Chung K.F. Eur. Respir. J. 16:2000;1158. (b) Renauld J.C. J. Clin. Pathol. 54:2001;577.
5. (a) For reviews of the subject, see: Stirling R.G., Chung K.F. Eur. Respir. J. 16:2000;1158 (b) Renauld J.C. J. Clin. Pathol. 54:2001;577.
6. Takacs has described a conceptually identical approach as a generalized synthesis of 4-substituted oxazolidin-2-ones. See: Takacs J.M., Jaber M.R., Vellekoop A.S. J. Org. Chem. 63:1998;2742.
7. (a) Prashad M., Kim H.-Y., Har D., Repic O., Blacklock T.J. Tetrahedron Lett. 39:1998;9369.
8. 3 method was also effective. See: Ho G.-J., Mathre D.J. J. Org. Chem. 60:1995;2271.
9. (a) Gage J.R., Evans D.A. Org. Syn. 68:1990;77.
10. (b) Note that the corresponding enantioselective addition of enolsilanes to benzyloxyacetaldehyde using chiral Cu(II) complexes does not work well for phenylacetate derivatives. See: Evans D.A., Kozlowski M.C., Murry J.A., Burgey C.S., Campos K.R., Connell B.T., Staples R.J. J. Am. Chem. Soc. 121:1999;669.
11. D=-71° for 1 (c=0.1, MeOH, 23°C; see ref 1).
12. Walker M.A., Heathcock C.H. J. Org. Chem. 56:1991;5747.
13. Evans D.A., Tedrow J.S., Shaw J.T., Downey C.W. J. Am. Chem. Soc. 124:2002;392.
14. 3H-thymidine (1 mCi/well) and then harvested and counted.
15. 5 cells/well. Compounds were dissolved in DMSO and serially diluted in media to give a final concentration of 0.3% DMSO. Compounds were added to cells 5 min prior to stimulating the cells with anti-CD3 (R&D Systems) at 1 mg/mL and anti-CD28 (Caltag Laboratories) at 200 μg/mL. Cells were cultured in a final volume of 200 μL at 37°C for 24 h. Supernatants were then harvested and cytokine levels measured by ELISA according to the manufacturer's instructions (Pharmingen).
16. 4 cells/well in serum free AIM V media (Gibco BRL) in 96-well plates with various concentrations of compound. After incubation for 24 h at 37°C, MTS (Promega) was added to each well at a final concentration of 333 μg/mL. Cell viability was determined after an additional 3 h incubation at 37°C by reading the plates at 490 nM absorbance. Inhibition was determined relative to cells cultured with 1% DMSO.
17. (a) Carda M., González F., Sánchez R., Marco J.A. Tetrahedron: Asymmetry. 13:2002;1005.
18. (b) After the completion of our work, Carda, et al. reported a variation of the aldol/Curtius strategy towards cytoxazone 1 (but not 9) that utilizes an unusual chiral ketone derived in five steps from L-erthrulose.
19. Seki M., Mori K. Eur. J. Org. Chem. 1999;2965.
20. Miyata O., Asai H., Naito T. Synlett. 1999;1915.
21. Madhan A., Kumar A.R., Rao B.V. Tetrahedron: Asymmetry. 12:2001;2009.
22. Hameršak Z., Ljubović E., Merćep M., Mesić M., Šunjić V. Synthesis. 2001;1989.
23. Park J.N., Ko S.Y., Koh H.Y. Tetrahedron Lett. 41:2000;5553.